Crinetics Pharmaceuticals
CRNX
61 hedge funds and large institutions have $229M invested in Crinetics Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 7 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
3% less funds holding
Funds holding: 63 → 61 (-2)
15.47% less ownership
Funds ownership: 78.42% → 62.95% (-15%)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
52% less capital invested
Capital invested by funds: $473M → $229M (-$244M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.33M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$2.81M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.78M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.57M |
| 5 |
Millennium Management
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$84.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.47M |
| 4 |
Goldman Sachs
New York
|
-$2.11M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.38M |
CRNX Hedge Fund Activity: Q3 2019 in Review
61 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2019, worth a combined $229M — down 52% from $473M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CRNX and 5 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was Opaleye Management, adding an estimated $3.33M. The largest seller was Vivo Capital, exiting entirely with an estimated $84.4M sold.
- 61 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2019, down from 63 in Q2 2019.
- Funds reported $229M of Crinetics Pharmaceuticals stock for Q3 2019, down 52% quarter-over-quarter.
- 5 funds opened new Crinetics Pharmaceuticals positions in Q3 2019 and 7 closed out, a net change of -2 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2019 was Opaleye Management, an estimated $3.33M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $84.4M sold.
Based on aggregated 13F filings for Q3 2019.